Bianca F. Goemans

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Detection of pathogens in the gut microbiome prior to bloodstream infection in children with acute myeloid leukemia or mature B-cell non-Hodgkin lymphoma.

Detection of pathogens in the gut microbiome prior to bloodstream infection in children with acute myeloid leukemia or mature B-cell non-Hodgkin lymphoma.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: April 02, 2026

Detection of Pathogens in the Gut Microbiome Prior to Bloodstream Infection in Children with Acute Myeloid Leukemia or Mature B-Cell Non-Hodgkin Lymphoma.

Detection of Pathogens in the Gut Microbiome Prior to Bloodstream Infection in Children with Acute Myeloid Leukemia or Mature B-Cell Non-Hodgkin Lymphoma.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: April 02, 2026

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Journal: Trials

Published: February 13, 2026

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse.

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse.

Journal: Pediatric blood & cancer

Published: December 10, 2025

CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

Journal: Blood

Published: July 14, 2025

Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed/refractory acute myeloid leukemia: a real-world experience.

Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed/refractory acute myeloid leukemia: a real-world experience.

Journal: Haematologica

Published: June 10, 2025

Bone marrow lymphocyte dynamics during chemotherapy in pediatric acute myeloid leukemia.

Bone marrow lymphocyte dynamics during chemotherapy in pediatric acute myeloid leukemia.

Journal: HemaSphere

Published: May 04, 2025

Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325].

Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325].

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 13, 2025

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Journal: Blood

Published: March 31, 2025

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel.

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel.

Journal: Blood

Published: March 31, 2025

Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High-Income Country: A 15-Year Population-Based Overview.

Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High-Income Country: A 15-Year Population-Based Overview.

Journal: Pediatric blood & cancer

Published: November 21, 2024

Predisposition Footprints in the Somatic Genome of Wilms Tumors.

Predisposition Footprints in the Somatic Genome of Wilms Tumors.

Journal: Cancer discovery

Published: June 20, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026